Roivant Sciences
ROIV
Market cap $8.84B

11.95 USD

+0.31

2.66%

At close Nov 13, 4:00 PM EST

After hours

12.00

+0.05

0.42%

1 day

2.66%

5 days

2.31%

1 month

0.93%

3 months

5.19%

6 months

6.89%

Year to date

5.29%

1 year

32.04%

5 years

27.81%

10 years

27.81%

About: Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Employees: 908

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,759 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

132% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 28

24% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 82

15% more funds holding

Funds holding: 254 [Q1] → 291 (+37) [Q2]

3.65% more ownership

Funds ownership: 74.2% [Q1] → 77.85% (+3.65%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 19 [Q1] → 19 (+0) [Q2]

4% less capital invested

Capital invested by funds: $6.3B [Q1] → $6.08B (-$224M) [Q2]

14% less call options, than puts

Call options by funds: $10.5M | Put options by funds: $12.2M

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12.50

5%

upside

Avg. target

$16.90

41%

upside

High target

$18

51%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

HC Wainwright & Co. Douglas Tsao 61% 1-year accuracy 95 / 157 met price target	51%upside $18	Buy Reiterated	13 Nov 2024
HC Wainwright & Co. Douglas Tsao 61% 1-year accuracy 95 / 157 met price target	51%upside $18	Buy Reiterated	19 Sept 2024
B of A Securities Chi Fong 0 / 0 met price target	5%upside $12.50	Neutral Maintained	11 Sept 2024
HC Wainwright & Co. Douglas Tsao 61% 1-year accuracy 95 / 157 met price target	51%upside $18	Buy Reiterated	11 Sept 2024
HC Wainwright & Co. Douglas Tsao 61% 1-year accuracy 95 / 157 met price target	51%upside $18	Buy Reiterated	19 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ROIV published over the past 30 days

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Ben Zimmer - Chief Executive Officer, Priovant Conference Call Participants Louise Chen - Cantor Brian Cheng - JPMorgan Joyce Zhou - TD Cowen Andy Chen - Wolfe Research Douglas Tsao - H.C.

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.21.

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update.

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant have bolstered Roivant's cash reserves. Key potential catalysts include Immunovant's batoclimab in Phase 3 trials and namilumab in a Phase 2 trial, though drug candidate performance remains a critical risk factor.

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Roivant Flips a Skin Drug to Organon

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.

Roivant Flips a Skin Drug to Organon

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Zacks Investment Research

Does Montes Archimedes Acquisition (ROIV) Have the Potential to Rally 35.12% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Montes Archimedes Acquisition (ROIV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Montes Archimedes Acquisition (ROIV) Have the Potential to Rally 35.12% as Wall Street Analysts Expect?

See News Rankings

Charts implemented using Lightweight Charts™